US 11,945,826 B2
Hydroxypyridoxazepines as NRF2 activators
Mark Elban, Collegeville, PA (US); Michal Pawel Glogowski, Collegeville, PA (US); Michael Clinton Koetting, Collegeville, PA (US); Brian Griffin Lawhorn, Collegeville, PA (US); Jay M. Matthews, Collegeville, PA (US); and Jaclyn Renee Patterson, Collegeville, PA (US)
Assigned to GlaxoSmithKline Intellectual Property Development Limited, Stevenage (GB)
Appl. No. 17/429,088
Filed by GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED, Middlesex (GB)
PCT Filed Feb. 11, 2020, PCT No. PCT/IB2020/051100
§ 371(c)(1), (2) Date Aug. 6, 2021,
PCT Pub. No. WO2020/165776, PCT Pub. Date Aug. 20, 2020.
Claims priority of provisional application 62/931,877, filed on Nov. 7, 2019.
Claims priority of provisional application 62/806,201, filed on Feb. 15, 2019.
Prior Publication US 2022/0204526 A1, Jun. 30, 2022
Int. Cl. C07D 498/04 (2006.01); C07D 498/10 (2006.01)
CPC C07D 498/04 (2013.01) [C07D 498/10 (2013.01); C07B 2200/13 (2013.01)] 31 Claims
 
1. A compound of Formula (I):

OG Complex Work Unit Chemistry
wherein:
R is hydrogen or methyl;
R′ is hydrogen or methyl;
R1 is hydrogen, —OH, —C1-3alkyl, —CF3, difluoromethyl, or halo;
Y is hydrogen, —C1-5alkyl, —C3-7cycloalkyl, —CF3, —CHF2, —CH2CF3; and
Y′ is hydrogen, —C1-5alkyl, —C3-7cycloalkyl, —CF3, —CHF2, —CH2CF3; or Y and Y′ form —C3-7cycloalkyl;
or a pharmaceutically acceptable salt thereof, or a tautomer thereof, or a hydrate thereof.